Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits-Reference-Cited by-同舟云学术

Antiatherogenic effects of newly developed apolipoprotein A-I mimetic peptide/phospholipid complexes against aortic plaque burden in Watanabe-heritable hyperlipidemic rabbits

Published:2011-10 Issue:2 Volume:218 Page:300-307
ISSN:0021-9150
Container-title:Atherosclerosis
language:en
Short-container-title:Atherosclerosis

Author:

Iwata Atsushi,Miura Shin-ichiro,Zhang Bo,Imaizumi Satoshi,Uehara Yoshinari,Shiomi Masashi,Saku Keijiro

Funder

Ministry of Education, Culture, Sports, Science and Technology

Pfizer

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference27 articles.

1. Acceleration of reverse cholesterol transport;von Eckardstein;Curr Opin Cardiol,2000

2. High-density lipoprotein – the clinical implications of recent studies;Gordon;N Engl J Med,1989

4. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis;Ibanez;J Am Coll Cardiol,2008

5. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial;Nissen;J Am Med Assoc,2003

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver X receptors: From pharmacology to nanoparticle-based drug delivery;European Journal of Pharmacology;2023-10

2. A Current Update on the Role of HDL-Based Nanomedicine in Targeting Macrophages in Cardiovascular Disease;Pharmaceutics;2023-05-15

3. Anti-atherosclerosis Related Drugs Based on High-Density Lipoprotein Metabolism and Remodeling Process;PROG BIOCHEM BIOPHYS;2023

4. High density lipoprotein as a therapeutic target: Focus on its functionality;BIOCELL;2023

5. Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future Challenges;Critical Reviews™ in Therapeutic Drug Carrier Systems;2023